Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 2/20 | 0.41 |
| ▸ | ICAM1 | P05362 | 2/20 | 0.41 |
| ▸ | ITGAL | P20701 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | MMP3 | P08254 | 1/20 | 0.38 |
| ▸ | CALCA | P06881 | 2/20 | 0.38 |
| ▸ | ITGA4 | P13612 | 5/20 | 0.37 |
| ▸ | DGAT1 | O75907 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.37 |
| ▸ | CCR1 | P32246 | 1/20 | 0.37 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6807946 | 0.92 | GAA (0.44) | ITGB2ICAM1ITGALPOLBCALCA | |
| SCHEMBL6807369 | 0.91 | ITGB2 (0.45) | ITGB2ICAM1ITGALPOLBMMP3 | |
| SCHEMBL6812952 | 0.91 | ITGB2 (0.41) | ITGB2ICAM1ITGALPOLBITGA4 | |
| SCHEMBL6808861 | 0.90 | CCR2 (0.51) | ITGB2ICAM1ITGALPOLBCCR2 | |
| SCHEMBL6807444 | 0.89 | ITGB2 (0.42) | ITGB2ICAM1ITGALITGA4ITGB1 | |
| SCHEMBL6803484 | 0.89 | POLB (0.55) | ITGB2ICAM1ITGALPOLBITGA4 | |
| SCHEMBL6803788 | 0.88 | ITGB2 (0.42) | ITGB2ICAM1ITGALITGA4ITGB1 | |
| SCHEMBL6807848 | 0.88 | TACR1 (0.40) | ITGB2ICAM1ITGALPOLBMMP3 | |
| SCHEMBL6807166 | 0.88 | POLB (0.42) | ITGB2ICAM1ITGALPOLBPSMB5 | |
| SCHEMBL6807498 | 0.88 | ITGB1 (0.39) | ITGB2ICAM1ITGALPOLBITGA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | TORAY INDUSTRIES, INC. (JP) | 2004-02-26 | — | — | US | disclosed |
| EP-1323709-A1 | UREA DERIVATIVE AND ADHESIVE-MOLECULE INHIBITOR CONTAINING THE SAME AS ACTIVE INGREDIENT | TORAY INDUSTRIES, INC. (JP) | 2003-07-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040039040-A1 | Urea derivative and adhesive-molecule inhibitor containing the same as active ingredient | ICAM1, VCAM1, EPCAM | ITGB2 59/4885ICAM1 1/4885ITGAL 174/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.